Supplementary Materials

A polygenic predictor of treatment-resistant depression using whole exome sequencing and genome-wide genotyping

Chiara Fabbri ¹, Siegfried Kasper ², Alexander Kautzky ², Joseph Zohar ³, Daniel Souery ⁴, Stuart Montgomery ⁵, Diego Albani ⁶, Gianluigi Forloni ⁶, Panagiotis Ferentinos ⁷, Dan Rujescu ⁸, Julien Mendlewicz ⁹, Rudolf Uher ¹⁰, Cathryn M. Lewis ¹, Alessandro Serretti ¹¹

1: Institute of Psychiatry, Psychology and Neuroscience, King's College London, United Kingdom

2: Department of Psychiatry and Psychotherapy, Medical University Vienna, Austria

3: Department of Psychiatry, Sheba Medical Center, Tel Hashomer, and Sackler School of Medicine, Tel Aviv University, Israel

4: Laboratoire de Psychologie Medicale, Universitè Libre de Bruxelles and Psy Pluriel, Centre Européen de Psychologie Medicale, Brussels

5: Imperial College School of Medicine, London, UK

6: Laboratory of Biology of Neurodegenerative Disorders, Neuroscience Department, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy

7: Department of Psychiatry, Athens University Medical School, Athens, Greece

8: University Clinic for Psychiatry, Psychotherapy and Psychosomatic, Martin-Luther-University Halle-Wittenberg, Germany

9: Universite' Libre de Bruxelles

10: Department of Psychiatry, Dalhousie University, Halifax, Nova Scotia, Canada

11. Department of Biomedical and NeuroMotor Sciences, University of Bologna, Italy

Table of contents

Supplementary Methods	p. 2
Supplementary Table 1	p. 6
Supplementary Table 2	p. 7
Supplementary Table 3	p. 7
Supplementary Table 4	p. 8
Supplementary Table 5	p. 8
Supplementary Table 6	p. 9
Supplementary Table 7	p. 10
Supplementary Table 8	p. 13
Supplementary Table 9	p. 15
Supplementary Table 10	p. 18
Supplementary Table 11	p. 20
Supplementary Table 12	p. 20
Supplementary Figure 1	p. 22
Supplementary Figure 2	p. 22
Supplementary Figure 3	p. 23
Supplementary Figure 4	p. 23
Supplementary Figure 5	p. 24
Supplementary Figure 6	p. 25
References	p. 25

Supplementary Methods

DNA extraction in GSRD

Genomic DNA was extracted from whole blood with an automated nucleic acid extractor (Maxwell, Promega, US). Quantity and quality were checked by a nanoscale spectrophotometer and for samples having a 260/280 absorbance ratio below 1.2 the extraction process was repeated.

Whole exome sequencing, genotyping and quality control in GSRD

The initial quality control was performed using the FASTQ pipeline (1). Trimming of the reads with barcode sequences was performed with fastx trimmer from the fastx toolkit (2). To align the trimmed reads to the reference human genome (human assembly GRCh37/hg19) we used TopHat2 (3) with the parameters mate-inner-dist=118 for the paired reads, and mate-std-dev=52.

Variants were called using FreeBayes, a Bayesian genetic variant detector designed to find SNPs (single-nucleotide polymorphisms), indels (insertions and deletions), MNPs (multi-nucleotide polymorphisms), and complex events (composite insertion and substitution events). FreeBayes is

haplotype-based, in the sense that it calls variants based on the literal sequences of reads aligned to a particular target, not their precise alignment. This method avoids one of the core problems with alignment-based variant detection that identical sequences may have multiple possible alignments (4). Poorly called variants were pruned out (quality score < 30, leaving in only variants with base call accuracy of 99.9% (5)) and variants with read depth < 10 (6) were excluded. Variants with $\geq 2\%$ missing rate, indels > 5 bp and SNPs within 3 bp from an indel (7), variants without at least two reads balanced to each side of the site (RPR < 1 or RPL < 1) or without reads on both strands (SAF=0 or SAR=0) (8) were also excluded. We excluded subjects having genotyping rate $\leq 95\%$, gender discrepancies, cryptic relatedness (identity by descent (IBD)>0.1875(9)), abnormal heterozygosity and population outliers (outside five standard deviations from the mean for the first 20 population principal components). After quality control, mean read depth was 79.82 (SD 62.15). Indels were realigned using left-normalization, and multiallelic variants were split into individual VCF lines using BCFtools (https://samtools.github.io/bcftools/bcftools.html).

Population principal components were calculated on a linkage-disequilibrium-pruned set of variants with MAF \geq 0.02. Indeed it has been demonstrated that the inclusion of low frequency or rare variants does not improve the detection of population stratification (10).

Quality control of genome-wide data was performed in line with the criteria used for the exome sequence data and a previous study on this sample (11). Genome-wide data was imputed using the Michigan imputation server and the Haplotype Reference Consortium (HRC, version r1.1 2016) as reference panel (12). Only common variants (MAF > 0.02) were extracted from imputed data and pruned for poor imputation quality ($R^2 < 0.30$) (13).

The total number of rare and common variants shared between the exome sequence data and genomewide data was 161,130 and 129,610, respectively; 120,632 (74.9%) of the rare ones were imputed (in the array data) and 40,497 (25.1%) of them were sequenced/genotyped; 114,198 (88%) of the common variants were imputed (in the array data) and 15,412 were sequenced/genotyped. The shared variants were used to exclude samples with poor concordance as explained in the main manuscript (paragraph 3. Results).

Variant annotation and exome risk score in GSRD

We classified variants into a high functional group and intermediate functional group according to functional consequence scores from the Sequence Ontology (SO) project (14). The first group included variants with a functional consequence score ≥ 0.90 (frameshift, stop gained, splice region, splice acceptor, splice donor, coding sequence, start lost, incomplete terminal codon, stop lost) and

the second group included variants with a functional consequence score ≥ 0.70 (protein altering, missense, initiator codon, inframe deletion, inframe insertion).

Exome risk scores were calculated using different weighting methods for comparison purpose (Eigen, CADD and SO functional scores) as described in paragraph 2.4.2. of the main manuscript. Eigen and CADD score were estimated using predictive modelling based on a wide range of variant annotations, describing variant risk of damaging effects based on conservation, impact on protein function, structure,

Box 1

- anyVariant 20
- maybeRegulatoryOrIntron 60
- alsoUTR 65
- coding 70
- nonsynonymous 90
- LOF 95
- polyphenProbablyOrPossiblyDamaging 95
- SIFTDeleterious 100

gene transcription, chromatin structure and others. Eigen scores differently from CADD scores were calculated using unsupervised machine learning, meaning that variants were not labelled as benign or damaging in the training set, but this distinction was figured out by the model based on a number of variant annotations (15). When using Eigen and CADD score, we extracted the raw scores and rescaled them between 1-25 (to not have negative values). The used weights based on SO functional scores are reported in Box 1. When we used SO functional scores, gene scores were calculated using GeneVarAssoc and getVarScores software (16). For scores based on common variants, we created clumps around variants prioritized according to their functional scores (the variant with the highest functional score was kept), using a R² threshold of 0.5 and a window size of 30 Kbp. This approach was used instead of the classic clumping based on association p values because the scores we calculated were substantially based on variant functional consequences and not on the difference in frequency between cases and controls.

In terms of included gene sets, we downloaded Gene Ontology (GO), Reactome, Biocarta, KEGG and other canonical gene sets (pathway interaction database and signal transduction pathways) from the Molecular Signatures Database (MSigDB version 6.2) (17). In addition, we included gene sets from SynaptomeDB (18), gene sets previously associated with major depressive disorder (MDD) (19), schizophrenia (20) (21) or bipolar disorder (22). A total of 7266 gene sets and 18908 genes were considered. In order to avoid bigger genes from driving most of the effect of a gene set, we added a further weight ($\omega_{size,m}$) that reduced the score of a gene as a function of its number of variants ($\omega_{size,m} = 1+(s_m - \min\{s_i\})/(\max\{s_i\} - \min\{s_i\})$, where s_m : number of variants in a gene, min $\{s_i\}$: number of variants in the smallest gene, max $\{s_i\}$: number of variants in the biggest gene) (23).

Replication samples: STAR*D and GENDEP

The Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study was a NIMH-funded study aimed to determine the effectiveness of different treatments for patients with MDD who have

not responded to the first antidepressant treatment. Non-psychotic MDD (DSM-IV criteria) patients with age between 18 and 75 years were enrolled from primary care or psychiatric outpatient clinics. Severity of depression was assessed using the 16-item Quick Inventory of Depressive Symptomatology-Clinician Rated (QIDS-C16) at baseline, weeks 2, 4, 6, 9, and 12, while HRSD–17 was administered at each level entry and exit. All patients received citalopram in level 1. Participants without sufficient symptomatic benefit were eligible for randomization to level 2 treatments, which entail four switch options (sertraline, bupropion, venlafaxine, cognitive therapy) and three citalopram augment options (bupropion, buspirone, cognitive therapy). 1953 patients were included in the genetic study. Detailed description of the study design and population are reported elsewhere (24).

The Genome-Based Therapeutic Drugs for Depression (GENDEP) project was a 12-week partially randomized open-label pharmacogenetic study with two active treatment arms. 867 patients with unipolar depression (ICD-10 or DSM-IV criteria) aged 19–72 years were recruited at nine European centres. Eligible participants were allocated to flexible-dosage treatment with either escitalopram (10–30 mg daily, 499 subjects) or nortriptyline (50–150 mg daily, 368 subjects). Severity of depression was assessed weekly by the Montgomery-Asberg Depression Rating Scale (MADRS), Hamilton Rating Scale for Depression (HRSD–17) and Beck Depression Inventory (BDI). Detailed information about the GENDEP study has been previously reported (25).

In STAR*D longitudinal data referred to level 1 and level 2 were used to create the phenotypes. Response was defined as a QIDS-C16 < 13 [equivalent to MADRS of 22] and score decrease of at least 50% compared to baseline at level 1 exit, while TRD was defined as lack of response at level 2 exit. In GENDEP prospective data collected during the 12-week trial were combined with the retrospective information on previous antidepressant treatments of the current episode to determine the phenotypes. A decrease of at least 50% in MADRS score compared to baseline was used as the only criterion according to the available definition of response in this sample (26).

Genome-wide data in STAR*D were obtained using Affymetrix Human Mapping 500K Array Set in 969 subjects and Affymetrix Genome-Wide Human SNP Array 5.0 (Affymetrix, South San Francisco, California) in the remaining 979 samples, while in GENDEP Illumina Human610-quad bead chip (Illumina, Inc., San Diego) was used (25) (27). Further genotyping in both samples was performed by the Illumina Infinium Exome-24 v1.0 BeadChip that includes ~ 250K variants. Preimputation quality control was performed according to the following criteria: 1) variants with missing rate \geq 5%; 2) monomorphic variants; 3) subjects with genotyping rate < 97%; 4) subjects with gender discrepancies; 5) subjects with abnormal heterozygosity; 6) related subjects (identity by descent (IBD) >0.1875 (9)); 7) population outliers according to Eigensoft analysis of linkage-disequilibriumpruned genetic data (28); 8) GWAS-exome discordant and 9) non-white subjects in STAR*D. The number of included subjects after quality control and their clinical-demographic features are reported in Supplementary Table 12.

Gene- and pathway-based scores were calculated in STAR*D and GENDEP following the same approach used in GSRD. Rare and common variants were distinguished based on the MAF threshold $1/\sqrt{(2n)}$ where n was the sample size (29). Scores were adjusted for the same covariates used in the GSRD sample (population principal components and centre of recruitment). In GSRD and replication samples the scores were standardized to allow comparability.

Clinical risk scores were calculated in the replication samples using the same approach applied in GSRD, using the effect sizes obtained in GSRD training sample. In GENDEP there were no subjects with chronic depression according to the DSM-IV definition (duration of the episode of at least two years), thus we used 1 year as threshold to define chronic depression since there is some evidence that outcome is poorer after 1 year (30). The maximum number of depressive episodes in GENDEP was 3, thus we used 2 (3rd quantile) as threshold instead of 4 (which corresponded to the 3rd quantile in GSRD sample). In STAR*D the MADRS scale was not available, thus we used QIDS-C16 item 11 (view of myself) and item 12 (suicidality) to calculate the pessimism score and items 10 (concentration), 13 (general interest), 14 (energy level) and 15 (feeling slow down) to calculate the interest activity score.

Supplementary Table 1: clinical-demographic characteristics of patients included in the training sample (n=847) and testing sample (n=362). Baseline MADRS refers to the beginning of the current depressive episode. BMI=body max index. MADRS=Montgomery and Åsberg Depression Rating Scale. TRD=treatment-resistant depression. Mean \pm standard deviation is reported for continuous variables and distribution for dichotomous ones. T tests, chi2 or Fisher's exact tests were used to calculate p values.

Variable	Training sample (n=847)	Testing sample (n=362)	p value
Age	51.44±13.94	51.87±14.16	0.63
Gender (F/M)	566/281	235/127	0.56
Education	Primary school n=59	Primary school n=29	0.43
	Secondary school n=309	Secondary school n=146	
	High school n=219	High school n=81	
	University n=253	University n=103	
Work status	Full time n=325	Full time n=137	0.73
	Part time n=70	Part time n=38	
	Retired n=169	Retired n=77	
	Student n=24	Student n=8	
	Unemployed n=215	Unemployed n=86	
	Other n=38	Other n=13	
Age at onset	36.85±14.95	35.94±15.70	0.37
Number of previous	3.61±2.77	3.77±2.92	0.44
depressive episodes			
Baseline MADRS score	34.56±7.36	33.85±7.69	0.14
Current MADRS score	24.73±11.13	24.78±11.60	0.95
Melancholic MDD	552/289	247/114	0.38
(yes/no)			

Psychotic features (yes/no)	40/551	16/244	0.85
Chronic depression (yes/no)	150/307	66/134	1
Current suicidal risk (yes/no)	416/430	176/186	0.91
Generalized anxiety disorder (yes/no)	87/759	41/321	0.66
Phenotype of interest	TRD n=353 Non-response n=291 Response n=203	TRD n=151 Non-response n=125 Response n=86	0.99
Treatment	Serotonergic n=421 Noradrenergic n=271 Serotonergic-noradrenergic n=128 Other n=27	Serotonergic n=192 Noradrenergic n=93 Serotonergic-noradrenergic n=59 Other n=18	0.10

Supplementary Table 2: number of variants available after quality control in the GSRD sample. SNP=single nucleotide polymorphism; insdel=insertion/deletions; MNPs=multi-nucleotide polymorphisms. SO=sequence ontology project. The number of variants with SO functional score ≥ 0.90 was lower than the number with SIFT > 0.95 and Polyphen > 0.15, but only the 73% of variants in the first group had a MAF<0.02 while 85% in both the other two groups.

Variant	All	MAF<0.02	SO functional	SIFT > 0.95	Polyphen > 0.15
type			score >=0.90		
SNP	1,134,094	996,390	35,150	89,810	106,962
Insdel	85,944	75,483	7,263	-	-
MNPs	9,097	7,874	256	437	471
Other	1,615	1,462	167	-	-
Total	1,230,750	1,081,209	42,836	90,247	107,433

Supplementary Table 3: clinical variables tested for possible association with TRD (TRD vs. response) and non-response (non-response vs. response) in the training sample only for predictor selection. The variables independently associated with the phenotype of interest after Bonferroni correction (alpha=0.0018) are highlighted in red and they were included in the clinical risk score. MADRS=Montgomery and Åsberg Depression Rating Scale. MADRS subscales were defined according to the previous literature and they were tested because of their previously found association with antidepressant response (31).

Variable	TRD vs. response p value	Non-response vs. response p
		value
Suicidality yes/no	6.32e-10	2.59e-06
Number of previous episodes	1.49e-04	0.0006
Psychotic depression yes/no	0.01	0.02
Melancholia yes/no	0.76	0.95
Chronic depression yes/no	2.29e-14	8.06e-08
MADRS baseline total	2.23e-04	0.92
MADRS baseline mood	2.5e-06	0.45
MADRS baseline mood-anxiety	6.58e-05	0.41
MADRS baseline anxiety	0.65	0.53
MADRS baseline cognition	7.58e-06	0.55

MADRS baseline pessimism	5.50e-04	0.55
MADRS baseline interest-activity	3.95e-05	0.67
MADRS baseline sleep	4.76e-03	0.48
MADRS baseline appetite	0.07	0.008
MADRS baseline vegetative	0.77	0.15
Age	0.03	0.16
Gender	1	0.58
BMI	0.01	0.26
Marital status	0.73	0.64
Work status	0.01	0.05
Age at onset	0.39	0.03
Duration of current episode	0.003	0.05
Generalized anxiety disorder yes/no	0.39	0.17
Panic disorder yes/no	0.056	0.58
Obssessive-compulsive disorder yes/no	0.67	0.35
Post-traumatic stress disorder yes/no	1	0.84
Thyroid disorder yes/no	0.61	0.23
Other medical illness yes/no	0.18	0.12

Supplementary Table 4: exome-wide distribution of variants with SO functional score ≥ 0.90 or ≥ 0.70 , SIFT deleterious (scores >0.95) and PolyPhen damaging/probably damaging variants (scores>0.15) among phenotypic groups. The mean number of alternative alleles and SD are reported in each phenotypic group.

Functional	TRD	Non-response	Response	TRD vs. resp.	TRD vs. non-resp. vs.
group					response
SO	2350.41±42.55	2352.5±52.24	2347.98±39.61	E= -0.002,	E=8.20e-05,
functional				SE=0.002, z= -0.81,	SE=0.0006, t=0.13,
score ≥ 0.90				p=0.42	p=0.89
SO	9854.19±134.44	9867.95±170.07	9854.35±129.58	E=0.001,	E= -0.0003,
functional				SE=0.0008, z=1.45,	SE=0.0002, t=-1.39,
score ≥ 0.70				p=0.15	p=0.16
SIFT score	1481.04±35.92	1484.33±39.27	1483.87±36.60	E=0.004,	E= -0.001, SE=0.0007,
>0.95				SE=0.002, z=1.82,	t=-1.44, p=0.15
				p=0.07	_
PolyPhen	1730.02±40.39	1730.82±46.68	1727.78±38.98	E=0.0002,	E=0.0002, SE=0.0006,
score >0.15				SE=0.002, z=0.10,	t=0.29, p=0.77
				p=0.92	

Supplementary Table 5: distribution of variants with SO functional score ≥ 0.90 per gene among phenotypic groups. The number of subjects carrying at least one alternative allele in a certain gene is also reported. For 14353 genes we observed at least one variant with SO functional score ≥ 0.90 . Only genes with p<1e-03 are reported.

TRD vs. response						
Gene	TRD n=504	Non-response n=416	Response n=289	Statistics		
ADGB	0.62±0.65	0.54±0.65	0.45±0.54	E= -0.52, SE=0.13, z=-		
	>=1 var. 266	>=1 var. 189 (45.4%)	>=1 var. 123 (42.6%)	3.85, p=1.1e-04		
	(52.8%)					
KIF18B	0.06±0.25	0.10±0.30	0.14±0.36	E=0.89, SE=0.26, z=3.38,		
	>=1 var. 30 (6%)	>=1 var. 41 (9.9%)	>=1 var. 39 (13.5%)	p=7.15e-04		
SMC1B	0.90±0.74	0.96±0.72	1.09±0.71	E=0.37, SE=0.11,		
	>=1 var. 339 (67%)	>=1 var. 299 (71.9%)	>=1 var. 228 (78.9%)	z=3.381, p=7.2e-04		
TRD - non-resp - response						
Gene	TRD	Non-response	Response	Statistics		

WDR90	0.042±0.20	0.0096±0.10	0.0069 ± 0.08	E= 0.62, SE=0.15, t=4.16,
	>=1 var 21 (4.1%)	>=1 var 4 (0.96%)	>=1 var 2 (0.69%)	p=3.44e-05
KIF18B	0.06±0.25	0.10±0.30	0.14±0.36	E= -0.29, SE=0.07, t=-
	>=1 var. 30 (6%)	>=1 var. 41 (9.9%)	>=1 var. 39 (13.5%)	3.90, p=1.006e-04
FAM169B	2.00±0.04	2.00±0.12	1.97±0.17	E= 0.71, SE=0.19, t=3.69,
	>2 var 1 (0.2%)	>2 var 3 (0.7%)	>2 var 0	p=2.35e-04
SMC1B	0.90±0.74	0.96±0.72	1.09±0.71	E= -0.11, SE=0.03, t=-
	>=1 var. 339 (67%)	>=1 var. 299 (71.9%)	>=1 var. 228 (78.9%)	3.62, p=3.04e-04
ENPP2	0	0.007 ± 0.08	0.28±0.18	E= -0.77, SE=0.21, t= -
		>=1 var 3 (0.7%)	>=1 var 7 (2.4%)	3.61, p=3.22e-04
ALDH3A1	0.008±0.09	0.19±0.14	0.04±0.21	E= -0.55, SE=0.15, t= -
	>=1 var 4 (0.8%)	>=1 var 8 (1.9%)	>=1 var 13 (4.5%)	3.56, p=3.90e-04
ADGB	0.62±0.65	0.54±0.65	0.45 ± 0.54	E= 0.12, SE=0.03, t=3.49,
	>=1 var. 266	>=1 var. 189(45.4%)	>=1 var. 123 (42.6%)	p=4.95e-04
	(52.8%)			
LOC101929680*	0.41±0.63	0.21±0.54	0.26±0.51	E= 0.12, SE=0.04, t=3.40,
	>=1 var 169 (33.5%)	>=1 var 108 (26%)	>=1 var 70 (24.3%)	p=7.00e-04
SCN9A*	0.41±0.63	0.21±0.54	0.26±0.51	E= 0.13, SE=0.04, t=3.40,
	>=1 var 169 (33.5%)	>=1 var 108 (26%)	>=1 var 70 (24.3%)	p=7.00e-04
KCNIP4	1.60±0.99	1.44±0.99	1.40 ± 0.90	E=0.08, SE=0.02, t=3.34,
	>=1 var 435 (86.3%)	>=1 var 399 (96%)	>=1 var 243 (84%)	8.74e-04

* SCN1A and SCN9A antisense RNA 1, its position mostly overlaps with SCN9A

Supplementary Table 6: distribution per gene of variants with SIFT score>0.95 in **A** (16483 genes had at least one of these variants) and PolyPhen score>0.15 in **B** (16947 genes had at least one of these variants) among phenotypic groups. The number of subjects carrying at least one alternative allele in a certain gene is also reported. Only genes with p<1e-03 are reported.

A

TRD vs. response					
Gene	TRD n=504	Non-response n=416	Response n=289	Statistics	
FLG	0.66±1.08	0.82±1.14	0.96±1.29	E=0.24, SE=0.07, z=3.51,	
	>=1 var 156 (31%)	>=1 var 166 (40%)	>=1 var 121 (42%)	p=4.46e-04	
LOC101927267*	0.04±0.19	0.06±0.25	0.09±0.30	E=1.14, SE=0.33, z=3.46,	
	>=1 var 19 (3.8%)	>=1 var 25 (6%)	>=1 var 25 (8.7%)	p=5.42e-04	
CR2	0.67±0.71	0.61±0.68	0.51±0.66	E=-0.41, SE=0.12, z=-3.40,	
	>=1 var 273 (54%)	>=1 var 210 (50%)	>=1 var 121 (42%)	p=6.70e-04	
PRPH*	0.04±0.19	0.06±0.25	0.09±0.29	E=1.15, SE=0.34, z=3.38,	
	>=1 var 18 (3.6%)	>=1 var 24 (5.8%)	>=1 var 24 (8.3%)	p=7.14e-04	
CHKB-CPT1B	0.01±0.11	0.02±0.13	0.04±0.20	E=1.71, SE=0.51, z=3.32,	
	>=1 var 6 (1.2%)	>=1 var 7 (1.7%)	>=1 var 12 (4.2%)	p=8.97e-04	
TRD - non-resp -	response				
Gene	TRD	Non-response	Response	Statistics	
EPX	0.68 ± 0.68	0.57±0.63	0.53±0.65	E=0.13, SE=0.03, t=3.88,	
	>=1 var 282 (56%)	>=1 var 205 (49.3%)	>=1 var 129 (44.6%)	p=1.11 e-04	
FLG	0.66 ± 1.08	0.82±1.14	0.96±1.29	E=-0.07, SE=0.02, t=-3.76,	
	>=1 var 156 (31%)	>=1 var 166 (40%)	>=1 var 121 (42%)	p=1.78e-04	
SLC35E4	0	0.01±0.011	0.03±0.16	E=-0.77, SE= 0.21, t=-3.63,	
		>=1 var 5 (1.2%)	>=1 var 8 (2.8%)	p=2.92e-04	
ABCA2	0.002 ± 0.04	0.02±0.14	0.03±0.16	E=-0.67, SE=0.19, t=-3.60,	
	>=1 var 1 (0.2%)	>=1 var 8 (1.9%)	>=1 var 8 (2.8%)	p=3.31e-04	
MIR3654	0.02±0.15	0.04±0.19	0.07±0.27	E=-0.38, SE=0.11, t=-3.51,	
	>=1 var 12 (2.4%)	>=1 var 16 (3.8%)	>=1 var 20 (6.9%)	p=4.61e-04	
TUT1	0.02±0.15	0.03±0.18	0.07±0.27	E=-0.39, SE=0.11, t=-3.51,	
	>=1 var 12 (2.4%)	>=1 var 14 (3.4%)	>=1 var 20 (6.9%)	p=4.69e-04	
SRR	0.10±0.31	0.08±0.28	0.04±0.19	E=0.28, SE=0.08, t=3.47,	
	>=1 var 48 (9.5%)	>=1 var 35 (8.4%)	>=1 var 11 (3.8%)	p=5.47e-04	

ACVRL1	0	0	0.02±0.13	E=-1.18, SE=0.34, t=-3.44,
			>=1 var 5 (1.7%)	p=5.97e-04
PRPH*	0.04±0.19	0.06±0.25	0.09±0.29	E=-0.32, SE=0.09, t=-3.39,
	>=1 var 18 (3.6%)	>=1 var 24 (5.8%)	>=1 var 24 (8.3%)	p=7.28e-04
LOC101927267*	0.04±0.19	0.06±0.25	0.09±0.30	E=-0.31, SE=0.09, t=-3.36,
	>=1 var 19 (3.8%)	>=1 var 25 (6%)	>=1 var 25 (8.7%)	p=7.94e-04

* LOC101927267 and PRPH show substantial position overlap

B

TRD vs. response					
Gene	TRD n=504	Non-response n=416	Response n=289	Statistics	
LOC101927267	0.04±0.19	0.06±0.25	0.09±0.30	E=1.14, SE=0.33, z=3.46,	
	>=1 var 19 (3.8%)	>=1 var 24 (5.8%)	>=1 var 25 (8.7%)	p=5.42e-04	
PRPH	0.04±0.19	0.06±0.25	0.09±0.29	E=1.15, SE=0.34, z=3.38,	
	>=1 var 18 (3.6%)	>=1 var 24 (5.8%)	>=1 var 24 (8.3%)	p=7.14e-04	
EPX	0.69±0.69	0.58±0.63	0.54±0.65	E=-0.40, SE=0.12, z=-3.31,	
	>=1 var 284 (56%)	>=1 var 209 (50%)	>=1 var 130 (45%)	p=9.46e-04	
MUC5B	0.79±1.15	0.87±1.21	1.10±1.34	E=0.21, SE=0.06, z=3.30,	
	>=1 var 221 (44%)	>=1 var 190 (45.7%)	>=1 var 153 (53%)	p=9.82e-04	
TRD vs. non-resp	vs. response	· · · · ·			
Gene	TRD	Non-response	Response	Statistics	
EPX	0.69±0.69	0.58±0.63	0.54±0.65	E=0.13, SE=0.03, t=3.92,	
	>=1 var 284	>=1 var 209 (50.2%)	>=1 var 130 (45%)	p=9.39e-05	
	(56.3%)				
PAGE1	0.008±0.09	0.03±0.17	0.06±0.29	E=-0.43, SE=0.12, t=-3.58,	
	>=1 var 4 (0.8%)	>=1 var 13 (3.1%)	>=1 var 13 (4.5%)	p=3.62e-04	
COL5A3	0.006±0.08	0.02±0.15	0.05±0.23	E=-0.51, SE=0.15, t=-3.51,	
	>=1 var 3 (0.6%)	>=1 var 9 (2.2%)	>=1 var 13 (4.5%)	p=4.61e-04	
SRR	0.10±0.31	0.08±0.28	0.04±0.19	E=0.28, SE=0.08, t= 3.47,	
	>=1 var 48 (9.5%)	>=1 var 35 (8.4%)	>=1 var 11 (3.8%)	p=5.47e-04	
LOC101927267	0.04±0.19	0.06±0.25	0.09±0.30	E=-0.32, SE=0.09, t=-3.44,	
	>=1 var 19 (3.8%)	>=1 var 24 (5.8%)	>=1 var 25 (8.7%)	p=5.91e-04	
OR4K5	0.02±0.14	0.05±0.22	0.06±0.24	E=-0.39, SE=0.11, t=-3.44,	
	>=1 var 10 (2%)	>=1 var 18 (4.3%)	>=1 var 17 (5.9%)	p=5.92e-04	
ENTPD8	0.02±0.15	0.007±0.08	0	E=0.70, SE=0.21, t=3.43,	
	>=1 var 11 (2.2%)	>=1 var 3 (9.7%)		p=6.19e-04	
MUC5B	0.79±1.15	0.87±1.21	1.10±1.34	E=-0.06, SE=0.02, t=-3.42,	
	>=1 var 221	>=1 var 190 (45.7%)	>=1 var 153 (53%)	p=6.57e-04	
	(43.8%)		~ /		
OGDH	0.04±0.20	0.01±0.12	0.003±0.06	E=0.51, SE=0.15, t=3.40,	
	>=1 var 20 (4%)	>=1 var 6 (1.4%)	>=1 var 1 (0.3%)	p=6.85e-04	
PRPH	0.04±0.19	0.06±0.25	0.09±0.29	E=-0.32, SE=0.09, t=-3.39,	
	>=1 var 18 (3.6%)	>=1 var 24 (5.8%))	>=1 var 24 (8.3%)	p=7.28e-04	
PLVAP	0.002±0.04	0.005±0.07	0.02±0.15	E=-0.81, SE=0.24, t=-3.33,	
	>=1 var 1 (0.2%)	>=1 var 2 (0.5%)	>=1 var 7 (2.4%)	p=8.88e-04	
PTPRA	0.05±0.23	0.04±0.19	0.01±0.10	E=0.38, SE=0.12, t=3.30,	
	>=1 var 27 (5.4%)	$\geq 1 \text{ var } 15(3.6\%)$	>=1 var 3 (1%)	p=9.96e-04	

Supplementary Table 7: association analyses of Eigen-weighted gene scores with the phenotypic groups. No association survived after Bonferroni correction (n of genes analysed: 21136). Only results with p<1e-03 are shown.

Whole sample, only rare variants					
TRD vs. response					
Gene	Е	SE	Z	р	
NBN	0.005	0.001	4.0	6.40e-05	
IDH1	0.007	0.002	3.80	1.46e-04	

ZNF418	0.009	0.002	3.67	2.43e-04
KRT19P2	0.009	0.002	3.64	2.78e-04
UBXN11	0.005	0.001	3.62	2.94e-04
PHF20L1	0.004	0.001	3.60	3.24e-04
OR4K5	0.009	0.003	3.421	6.25e-04
RORC	0.005	0.001	3.42	6.31e-04
LRP1	-0.003	0.0008	-3.37	7.39e-04
NODAL	0.009	0.003	3.37	7.49e-04
ELF3	0.005	0.002	3.35	8.16e-04
TOMM34	-0.007	0.002	-3.32	8.94e-04
FAM110A	-0.009	0.003	-3 30	9 51e-04
TRD vs. non-resi	n vs. response	01000	0.00	
Gene	E	SE	t	n
NBN	-0.0015	0.0004	-4 10	4 34e-05
ZNF418	-0.0024	0.0006	-4.06	5 18e-05
KRT19P2	-0.0024	0.0006	-3.03	9.04e-05
SCML4	-0.0023	0.0000	-3.75	1 84e-04
IDH1	-0.0013	0.0004	-3.73	1.03e.04
OP4K5	0.0019	0.0003	3.64	2.862.04
UDVN11	-0.0024	0.0007	-3.04	2.600-04
VATNA1	-0.0014	0.0004	-3.37	5.800.04
WEDC10D	-0.0019	0.0000	-3.43	5.02 04
NODAL	-0.0042	0.0012	-3.44	7.01 - 04
NODAL ELE2	-0.0028	0.0008	-3.40	7.462.04
	-0.0014	0.0004	-3.38	7.400-04
	-0.0007	0.0002	-3.57	7.75 - 04
POPC	0.0030	0.0009	2.25	2 41 ₂ 04
	-0.0013	0.0004	-3.33	8.612.04
SLF1	0.0019	0.0000	5.54	8.016-04
	eu with serotonergie a	antituepressants, only i		
TRD vs resnons	ρ			
TRD vs. response Gene	e F	SE	t	n
Gene	e E 0.009	SE	t 3 54	p 4 00e-04
Gene SUMF1	e E 0.009 0.007	SE 0.002 0.002	t 3.54 3.41	p 4.00e-04 6.56e-04
Gene SUMF1 LYPD6B PTPRU	e E 0.009 0.007 0.007	SE 0.002 0.002 0.002	t 3.54 3.41 3.40	p 4.00e-04 6.56e-04 6.83e-04
IRD vs. responseGeneSUMF1LYPD6BPTPRUTEX36-AS1	e E 0.009 0.007 0.007 0.007 0.015	SE 0.002 0.002 0.002 0.002 0.002	t 3.54 3.41 3.40 3.38	p 4.00e-04 6.56e-04 6.83e-04 7.15e-04
IRD vs. responseGeneSUMF1LYPD6BPTPRUTEX36-AS1ZNF418	e E 0.009 0.007 0.007 0.015 0.012	SE 0.002 0.002 0.002 0.002 0.005 0.004	t 3.54 3.41 3.40 3.38 3.32	p 4.00e-04 6.56e-04 6.83e-04 7.15e-04 8.94e-04
IRD vs. responseGeneSUMF1LYPD6BPTPRUTEX36-AS1ZNF418GZMM	e E 0.009 0.007 0.007 0.015 0.012 -0.014	SE 0.002 0.002 0.002 0.005 0.004	t 3.54 3.41 3.40 3.38 3.32 -3.32	p 4.00e-04 6.56e-04 6.83e-04 7.15e-04 8.94e-04 8.98e-04
TRD vs. responseGeneSUMF1LYPD6BPTPRUTEX36-AS1ZNF418GZMMTRHR	e E 0.009 0.007 0.007 0.015 0.012 -0.014 0.001	SE 0.002 0.002 0.002 0.005 0.004 0.004 0.0029	t 3.54 3.41 3.40 3.38 3.32 -3.32 3.31	p 4.00e-04 6.56e-04 6.83e-04 7.15e-04 8.94e-04 8.98e-04 9.40e-04
TRD vs. responseGeneSUMF1LYPD6BPTPRUTEX36-AS1ZNF418GZMMTRHRTRD vs. non-rest	e E 0.009 0.007 0.007 0.015 0.012 -0.014 0.001 0 vs. response	SE 0.002 0.002 0.002 0.005 0.004 0.004 0.0029	t 3.54 3.41 3.40 3.38 3.32 -3.32 3.31	p 4.00e-04 6.56e-04 6.83e-04 7.15e-04 8.94e-04 8.98e-04 9.40e-04
TRD vs. responseGeneSUMF1LYPD6BPTPRUTEX36-AS1ZNF418GZMMTRHRTRD vs. non-responseGene	e E 0.009 0.007 0.007 0.015 0.012 -0.014 0.001 p vs. response E	SE 0.002 0.002 0.002 0.005 0.004 0.0029	t 3.54 3.41 3.40 3.38 3.32 -3.32 3.31 t	p 4.00e-04 6.56e-04 6.83e-04 7.15e-04 8.94e-04 8.98e-04 9.40e-04
IRD vs. responseGeneSUMF1LYPD6BPTPRUTEX36-AS1ZNF418GZMMTRHRTRD vs. non-ressGeneZBTB32	e E 0.009 0.007 0.007 0.015 0.012 -0.014 0.001 p vs. response E -0.0044	SE 0.002 0.002 0.002 0.005 0.004 0.0029	t 3.54 3.41 3.40 3.38 3.32 -3.32 3.31 t -3.94	p 4.00e-04 6.56e-04 6.83e-04 7.15e-04 8.94e-04 8.98e-04 9.40e-04
IRD vs. responseGeneSUMF1LYPD6BPTPRUTEX36-AS1ZNF418GZMMTRHRTRD vs. non-responseGeneZBTB32UBXN11	e E 0.009 0.007 0.007 0.015 0.012 -0.014 0.001 p vs. response E -0.0044 -0.0018	SE 0.002 0.002 0.002 0.005 0.004 0.004 0.0029 SE 0.0011 0.0005	t 3.54 3.41 3.40 3.38 3.32 -3.32 3.31 t -3.94 -3.61	p 4.00e-04 6.56e-04 6.83e-04 7.15e-04 8.94e-04 8.98e-04 9.40e-04 p 9.15e-05 3.27e-04
TRD vs. responseGeneSUMF1LYPD6BPTPRUTEX36-AS1ZNF418GZMMTRHRTRD vs. non-responseGeneZBTB32UBXN11TAF1A	e E 0.009 0.007 0.007 0.015 0.012 -0.014 0.001 p vs. response E -0.0044 -0.0018 0.0034	SE 0.002 0.002 0.002 0.005 0.004 0.004 0.0029 SE 0.0011 0.0005 0.0010	t 3.54 3.41 3.40 3.38 3.32 -3.32 3.31 t -3.94 -3.61 3.55	p 4.00e-04 6.56e-04 6.83e-04 7.15e-04 8.94e-04 8.98e-04 9.40e-04 p 9 .15e-05 3.27e-04 4.11e-04
IRD vs. responseGeneSUMF1LYPD6BPTPRUTEX36-AS1ZNF418GZMMTRHRTRD vs. non-responseGeneZBTB32UBXN11TAF1ACHRDL2	e E 0.009 0.007 0.007 0.015 0.012 -0.014 0.001 vs. response E -0.0044 -0.0018 0.0034 -0.0012	SE 0.002 0.002 0.002 0.005 0.004 0.004 0.0029 SE 0.0011 0.0005 0.0010 0.0004	t 3.54 3.41 3.40 3.38 3.32 -3.32 3.31 t -3.94 -3.61 3.55 -3.55	p 4.00e-04 6.56e-04 6.83e-04 7.15e-04 8.94e-04 8.98e-04 9.40e-04 p 9 .15e-05 3.27e-04 4.11e-04
IRD vs. responseGeneSUMF1LYPD6BPTPRUTEX36-AS1ZNF418GZMMTRHRTRD vs. non-responseGeneZBTB32UBXN11TAF1ACHRDL2ZNF418	e E 0.009 0.007 0.007 0.015 0.012 -0.014 0.001 p vs. response E -0.0044 -0.0018 0.0034 -0.0012 -0.0012 -0.0012 -0.0030	SE 0.002 0.002 0.002 0.005 0.004 0.004 0.0029 SE 0.0011 0.0005 0.0010 0.0004	t 3.54 3.41 3.40 3.38 3.32 -3.32 3.31 t -3.94 -3.61 3.55 -3.55	p 4.00e-04 6.56e-04 6.83e-04 7.15e-04 8.94e-04 8.98e-04 9.40e-04 p 9.15e-05 3.27e-04 4.11e-04 4.13e-04
TRD vs. responseGeneSUMF1LYPD6BPTPRUTEX36-AS1ZNF418GZMMTRHRTRD vs. non-responseGeneZBTB32UBXN11TAF1ACHRDL2ZNF418SMYD1	e E 0.009 0.007 0.007 0.015 0.012 -0.014 0.001 p vs. response E -0.0044 -0.0018 0.0034 -0.0012 -0.0012 -0.0030 0.0015	SE 0.002 0.002 0.002 0.005 0.004 0.004 0.0029 SE 0.0011 0.0005 0.0010 0.0004 0.0005	t 3.54 3.41 3.40 3.38 3.32 -3.32 3.31 t -3.94 -3.61 3.55 -3.55 -3.55 3.54	p 4.00e-04 6.56e-04 6.83e-04 7.15e-04 8.94e-04 8.98e-04 9.40e-04 p 9.15e-05 3.27e-04 4.11e-04 4.13e-04 4.26e-04
IRD vs. responseGeneSUMF1LYPD6BPTPRUTEX36-AS1ZNF418GZMMTRHRTRD vs. non-responseGeneZBTB32UBXN11TAF1ACHRDL2ZNF418SMYD1GATS	e E 0.009 0.007 0.007 0.015 0.012 -0.014 0.001 p vs. response E -0.0044 -0.0018 0.0034 -0.0012 -0.0030 0.0015 -0.0030	SE 0.002 0.002 0.002 0.005 0.004 0.004 0.0029 SE 0.0011 0.0005 0.0010 0.0004 0.0005 0.0010 0.0004 0.0004 0.0004 0.0004 0.0004 0.0004 0.0004 0.0004 0.0008	t 3.54 3.41 3.40 3.38 3.32 -3.32 3.31 t -3.94 -3.61 3.55 -3.55 -3.55 3.54	p 4.00e-04 6.56e-04 6.83e-04 7.15e-04 8.94e-04 8.98e-04 9.40e-04 9.15e-05 3.27e-04 4.11e-04 4.13e-04 4.26e-04
TRD vs. responseGeneSUMF1LYPD6BPTPRUTEX36-AS1ZNF418GZMMTRHRTRD vs. non-responseGeneZBTB32UBXN11TAF1ACHRDL2ZNF418SMYD1GATSLYPD6B	E 0.009 0.007 0.007 0.015 0.012 -0.014 0.001 vs. response E -0.0044 -0.0018 0.0034 -0.0012 -0.0030 0.0015 -0.0030 -0.0020	SE 0.002 0.002 0.002 0.005 0.004 0.004 0.0029 SE 0.0011 0.0005 0.0010 0.0004 0.0004 0.0005 0.0010 0.0004 0.0004 0.0004 0.0004 0.0009 0.0004 0.0008 0.0006	t 3.54 3.41 3.40 3.38 3.32 -3.32 3.31 t -3.94 -3.61 3.55 -3.55 3.54 -3.54 -3.54 -3.52	p 4.00e-04 6.56e-04 6.83e-04 7.15e-04 8.94e-04 8.98e-04 9.40e-04 9.40e-04 4.11e-04 4.11e-04 4.13e-04 4.26e-04 4.58e-04
TRD vs. responseGeneSUMF1LYPD6BPTPRUTEX36-AS1ZNF418GZMMTRHRTRD vs. non-responseGeneZBTB32UBXN11TAF1ACHRDL2ZNF418SMYD1GATSLYPD6BTTC23L	E 0.009 0.007 0.007 0.015 0.012 -0.014 0.001 vs. response E -0.0044 -0.0018 0.0034 -0.0030 0.0015 -0.0030 0.0015 -0.0020 0.0018	SE 0.002 0.002 0.002 0.005 0.004 0.004 0.0029 SE 0.0011 0.0005 0.0010 0.0004 0.0005 0.0010 0.0004 0.0009 0.0004 0.0008 0.0006 0.0005	t 3.54 3.41 3.40 3.38 3.32 -3.32 3.31 t -3.94 -3.61 3.55 -3.55 -3.55 -3.54 -3.54 -3.52 3.40	p 4.00e-04 6.56e-04 6.83e-04 7.15e-04 8.94e-04 8.98e-04 9.40e-04 9.40e-04 4.11e-04 4.11e-04 4.13e-04 4.26e-04 4.58e-04 5.26e-04
TRD vs. responseGeneSUMF1LYPD6BPTPRUTEX36-AS1ZNF418GZMMTRHRTRD vs. non-responseGeneZBTB32UBXN11TAF1ACHRDL2ZNF418SMYD1GATSLYPD6BTTC23LIFNA4	e E 0.009 0.007 0.007 0.015 0.012 -0.014 0.001 vs. response E -0.0044 -0.0018 0.0034 -0.0012 -0.0030 0.0015 -0.0030 0.0015 -0.0030 -0.0020 0.0018 -0.0020 0.0018 -0.0053	SE 0.002 0.002 0.002 0.005 0.004 0.004 0.0029 SE 0.0011 0.0005 0.0010 0.0004 0.0005 0.0010 0.0004 0.0004 0.0005 0.0004 0.0008 0.0006 0.0005 0.0015	t 3.54 3.41 3.40 3.38 3.32 -3.32 3.31 t -3.94 -3.61 3.55 -3.55 -3.55 -3.54 -3.54 -3.52 3.40 -3.46	P 4.00e-04 6.56e-04 6.83e-04 7.15e-04 8.94e-04 8.98e-04 9.40e-04 9.40e-04 9.15e-05 3.27e-04 4.11e-04 4.13e-04 4.26e-04 5.26e-04 5.79e-04
IRD vs. responseGeneSUMF1LYPD6BPTPRUTEX36-AS1ZNF418GZMMTRHRTRD vs. non-respGeneZBTB32UBXN11TAF1ACHRDL2ZNF418SMYD1GATSLYPD6BTTC23LIFNA4KRT19P2	e E 0.009 0.007 0.007 0.015 0.012 -0.014 0.001 p vs. response E -0.0044 -0.0018 0.0034 -0.0020 0.0015 -0.0020 0.0018 -0.0053 -0.0031	SE 0.002 0.002 0.002 0.005 0.004 0.004 0.0029 SE 0.0011 0.0005 0.0010 0.0004 0.0005 0.0010 0.0004 0.0004 0.0005 0.0004 0.0008 0.0006 0.0005 0.0015 0.0009	t 3.54 3.41 3.40 3.38 3.32 -3.32 3.31 t -3.94 -3.61 3.55 -3.55 -3.55 3.54 -3.52 3.49 -3.46 -3.45	p 4.00e-04 6.56e-04 6.83e-04 7.15e-04 8.94e-04 8.98e-04 9.40e-04 9.40e-04 9.15e-05 3.27e-04 4.11e-04 4.11e-04 4.26e-04 4.29e-04 5.26e-04 5.79e-04 5.91e-04
IRD vs. responseGeneSUMF1LYPD6BPTPRUTEX36-AS1ZNF418GZMMTRHRTRD vs. non-respGeneZBTB32UBXN11TAF1ACHRDL2ZNF418SMYD1GATSLYPD6BTTC23LIFNA4KRT19P2HERC6	e E 0.009 0.007 0.007 0.015 0.012 -0.014 0.001 p vs. response E -0.0044 -0.0018 0.0034 -0.0012 -0.0030 0.0015 -0.0030 0.0015 -0.0020 0.0018 -0.0053 -0.0031 0.0021	SE 0.002 0.002 0.002 0.005 0.004 0.004 0.0029 SE 0.0011 0.0005 0.0010 0.0004 0.0005 0.0010 0.0004 0.0005 0.0004 0.0004 0.0005 0.0004 0.0005 0.0005 0.0005 0.0015 0.0009 0.0009 0.0009 0.0009	t 3.54 3.41 3.40 3.38 3.32 -3.32 3.31 t -3.94 -3.61 3.55 -3.55 -3.55 3.54 -3.52 3.49 -3.46 -3.45 3.44	p 4.00e-04 6.56e-04 6.83e-04 7.15e-04 8.94e-04 8.98e-04 9.40e-04 9.40e-04 9.15e-05 3.27e-04 4.11e-04 4.11e-04 4.26e-04 4.29e-04 5.26e-04 5.79e-04 6.18e-04
IRD vs. responseGeneSUMF1LYPD6BPTPRUTEX36-AS1ZNF418GZMMTRHRTRD vs. non-respGeneZBTB32UBXN11TAF1ACHRDL2ZNF418SMYD1GATSLYPD6BTTC23LIFNA4KRT19P2HERC6EFHC1	E 0.009 0.007 0.007 0.015 0.012 -0.014 0.001 v vs. response E -0.0044 -0.0018 0.0034 -0.0015 -0.0030 0.0015 -0.0030 -0.0013 -0.0013 -0.0013 -0.0014	SE 0.002 0.002 0.002 0.002 0.003 0.004 0.004 0.0029 SE 0.0011 0.0005 0.0010 0.0004 0.0005 0.0010 0.0004 0.0005 0.0004 0.0004 0.0008 0.0005 0.0015 0.0009 0.0009 0.0006 0.0007	t 3.54 3.41 3.40 3.38 3.32 -3.32 3.31 t -3.94 -3.61 3.55 -3.55 3.54 -3.55 3.54 -3.52 3.49 -3.46 -3.45 3.44 -3.43	p 4.00e-04 6.56e-04 6.83e-04 7.15e-04 8.94e-04 8.98e-04 9.40e-04 9.40e-04 9.15e-05 3.27e-04 4.11e-04 4.11e-04 4.26e-04 5.26e-04 5.79e-04 5.91e-04 6.18e-04
IRD vs. responseGeneSUMF1LYPD6BPTPRUTEX36-AS1ZNF418GZMMTRHRTRD vs. non-responseGeneZBTB32UBXN11TAF1ACHRDL2ZNF418SMYD1GATSLYPD6BTTC23LIFNA4KRT19P2HERC6EFHC1PTPRU	E 0.009 0.007 0.015 0.012 -0.014 0.001 vs. response E -0.0044 -0.0018 0.0034 -0.0030 0.0015 -0.0030 -0.0031 0.0021 -0.0023 -0.0018	SE 0.002 0.002 0.002 0.005 0.004 0.004 0.0029 SE 0.0011 0.0005 0.0010 0.0004 0.0005 0.0010 0.0004 0.0005 0.0004 0.0008 0.0006 0.0005 0.0006 0.0006 0.0007 0.0005	$ \begin{array}{c} \mathbf{t} \\ 3.54 \\ 3.41 \\ 3.40 \\ 3.38 \\ 3.32 \\ -3.32 \\ 3.31 \\ \hline \\ \mathbf{t} \\ -3.94 \\ -3.61 \\ 3.55 \\ -3.55 \\ -3.55 \\ -3.55 \\ -3.55 \\ -3.55 \\ -3.54 \\ -3.54 \\ -3.54 \\ -3.52 \\ 3.49 \\ -3.46 \\ -3.45 \\ 3.44 \\ -3.43 \\ -3.43 \\ -3.42 \\ \end{array} $	p 4.00e-04 6.56e-04 6.83e-04 7.15e-04 8.94e-04 8.98e-04 9.40e-04 9.40e-04 9.15e-05 3.27e-04 4.11e-04 4.13e-04 4.26e-04 5.26e-04 5.79e-04 5.91e-04 6.18e-04 6.49e-04
IRD vs. responseGeneSUMF1LYPD6BPTPRUTEX36-AS1ZNF418GZMMTRHRTRD vs. non-responseGeneZBTB32UBXN11TAF1ACHRDL2ZNF418SMYD1GATSLYPD6BTTC23LIFNA4KRT19P2HERC6EFHC1PTPRUTMEM67	E 0.009 0.007 0.015 0.012 -0.014 0.001 vs. response E -0.0044 -0.0018 0.0034 -0.0030 0.0015 -0.0030 0.0015 -0.0030 -0.0030 -0.0015 -0.0030 -0.0020 0.0018 -0.0053 -0.0021 -0.0023 -0.0018 -0.0017	SE 0.002 0.002 0.002 0.005 0.004 0.004 0.0029 SE 0.0011 0.0005 0.0010 0.0004 0.0005 0.0010 0.0004 0.0005 0.0004 0.0008 0.0006 0.0005 0.0006 0.0007 0.0005 0.0005	$\begin{array}{c} \mathbf{t} \\ 3.54 \\ 3.41 \\ 3.40 \\ 3.38 \\ 3.32 \\ -3.32 \\ 3.31 \\ \hline \\ \mathbf{t} \\ -3.94 \\ -3.61 \\ 3.55 \\ -3.55 \\ -3.55 \\ -3.55 \\ -3.55 \\ -3.55 \\ -3.55 \\ -3.55 \\ -3.55 \\ -3.55 \\ -3.55 \\ -3.55 \\ -3.55 \\ -3.54 \\ -3.45 \\ -3.44 \\ -3.43 \\ -3.42 \\ -3.42 \\ -3.42 \\ -3.42 \\ -3.42 \\ -3.42 \\ -3.42 \\ \end{array}$	P 4.00e-04 6.56e-04 6.83e-04 7.15e-04 8.94e-04 8.98e-04 9.40e-04 9.40e-04 9.15e-05 3.27e-04 4.11e-04 4.11e-04 4.26e-04 5.26e-04 5.79e-04 5.91e-04 6.18e-04 6.49e-04 6.68e-04 6.71e-04
IRD vs. responseGeneSUMF1LYPD6BPTPRUTEX36-AS1ZNF418GZMMTRHRTRD vs. non-responseGeneZBTB32UBXN11TAF1ACHRDL2ZNF418SMYD1GATSLYPD6BTTC23LIFNA4KRT19P2HERC6EFHC1PTPRUTMEM67SLPI	e E 0.009 0.007 0.007 0.015 0.012 -0.014 0.001 p vs. response E -0.0044 -0.0018 0.0034 -0.0012 -0.0030 0.0015 -0.0030 0.0015 -0.0030 0.0015 -0.0020 0.0018 -0.0020 0.0018 -0.0023 -0.0023 -0.0018 -0.0017 0.0026	SE 0.002 0.002 0.002 0.005 0.004 0.004 0.0029 SE 0.0011 0.0005 0.0010 0.0004 0.0005 0.0010 0.0004 0.0005 0.0004 0.0009 0.0006 0.0005 0.0005 0.0006 0.0007 0.0005 0.0005 0.0005 0.0005 0.0005 0.0005 0.0005	$\begin{array}{c} \mathbf{t} \\ 3.54 \\ 3.41 \\ 3.40 \\ 3.38 \\ 3.32 \\ -3.32 \\ 3.31 \\ \hline \\ \mathbf{t} \\ -3.94 \\ -3.61 \\ 3.55 \\ -3.52 \\ -3.4$	P 4.00e-04 6.56e-04 6.83e-04 7.15e-04 8.94e-04 8.98e-04 9.40e-04 9.40e-04 9.15e-05 3.27e-04 4.11e-04 4.11e-04 4.26e-04 4.29e-04 5.26e-04 5.79e-04 6.18e-04 6.49e-04 6.68e-04 6.71e-04 7.33e-04
IRD vs. responseGeneSUMF1LYPD6BPTPRUTEX36-AS1ZNF418GZMMTRHRTRD vs. non-respGeneZBTB32UBXN11TAF1ACHRDL2ZNF418SMYD1GATSLYPD6BTTC23LIFNA4KRT19P2HERC6EFHC1PTPRUTMEM67SLPISCML4	E 0.009 0.007 0.015 0.012 -0.014 0.001 vs. response E -0.0044 -0.0012 -0.0030 0.0015 -0.0030 0.0015 -0.0030 0.0015 -0.0030 -0.0018 -0.0053 -0.0031 0.0021 -0.0018 -0.0017 0.0023 -0.0017 0.0026 -0.0019	SE 0.002 0.002 0.002 0.005 0.004 0.004 0.0029 SE 0.0011 0.0005 0.0010 0.0004 0.0005 0.0010 0.0004 0.0005 0.0004 0.0009 0.0006 0.0005 0.0005 0.0006 0.0007 0.0005 0.0005 0.0005 0.0005 0.0005 0.0005 0.0005	$\begin{array}{c c c c c c c c c c c c c c c c c c c $	P 4.00e-04 6.56e-04 6.83e-04 7.15e-04 8.94e-04 8.98e-04 9.40e-04 9.40e-04 9.15e-05 3.27e-04 4.11e-04 4.11e-04 4.129e-04 5.26e-04 5.79e-04 5.91e-04 6.18e-04 6.49e-04 6.71e-04 7.33e-04 7.45e-04
IRD vs. responseGeneSUMF1LYPD6BPTPRUTEX36-AS1ZNF418GZMMTRHRTRD vs. non-respGeneZBTB32UBXN11TAF1ACHRDL2ZNF418SMYD1GATSLYPD6BTTC23LIFNA4KRT19P2HERC6EFHC1PTPRUTMEM67SLPISCML4CCDC8	E 0.009 0.007 0.007 0.015 0.012 -0.014 0.001 v vs. response E -0.0044 -0.0012 -0.0030 0.0015 -0.0030 -0.0012 -0.0030 -0.0015 -0.0020 0.0018 -0.0053 -0.0018 -0.0017 0.0026 -0.0019 0.0044	SE 0.002 0.002 0.002 0.005 0.004 0.004 0.0029 SE 0.0011 0.0005 0.0010 0.0004 0.0005 0.0010 0.0004 0.0005 0.0004 0.0004 0.0005 0.0006 0.0005 0.0005 0.0005 0.0005 0.0005 0.0005 0.0005 0.0005 0.0005 0.0005 0.0005 0.0005 0.0005	$\begin{array}{c} \mathbf{t} \\ 3.54 \\ 3.41 \\ 3.40 \\ 3.38 \\ 3.32 \\ -3.32 \\ 3.31 \\ \hline \\ \mathbf{t} \\ -3.94 \\ -3.61 \\ 3.55 \\ -3.55 \\ -3.55 \\ -3.55 \\ -3.55 \\ -3.55 \\ -3.55 \\ -3.55 \\ -3.55 \\ -3.55 \\ -3.54 \\ -3.44 \\ -3.43 \\ -3.45 \\ 3.44 \\ -3.43 \\ -3.42 \\ -3.42 \\ -3.42 \\ -3.42 \\ -3.42 \\ -3.39$	p 4.00e-04 6.56e-04 6.83e-04 7.15e-04 8.94e-04 8.98e-04 9.40e-04 9.40e-04 9.15e-05 3.27e-04 4.11e-04 4.11e-04 4.12e-04 4.26e-04 5.26e-04 5.79e-04 5.91e-04 6.18e-04 6.71e-04 7.33e-04 7.45e-04 8.28e-04

PTPRT	0.0009	0.0003	3.32	9.52e-04			
Subsample treate	Subsample treated with noradrenergic antidepressants, only rare variants						
TRD vs. response	e		v				
Gene	E	SE	t	D			
IFT80	0.01	0.003	3.34	8.24e-04			
RPGRIP1L	0.01	0.003	3.33	8.60e-04			
TRD vs. non-res	o vs. response			•			
Gene	E	SE	t	D			
KCNK15	-0.005	0.001	-3.93	1.04e-04			
RNF144A	0.003	0.0008	3.64	3.16e-04			
CCNT2-AS1	-0.004	0.001	-3.60	3.64e-04			
RPGRIP1L	-0.003	0.0007	-3.56	4.23e-04			
ACMSD	-0.004	0.001	-3.47	5.80e-04			
CLK1	-0.002	0.0007	-3.40	7.49e-04			
PRR23A	-0.005	0.002	-3.40	7.50e-04			
COTL1	0.003	0.0009	3.37	8.37e-04			
GDPD5	-0.002	0.0006	-3.33	9.76e-04			
Whole sample, ra	are + common varian	ts					
TRD vs. response	e						
Gene	E	SE	t	D			
NBN	0.0051	0.0012	4.16	3.14e-05			
ZNF418	0.0094	0.0024	3.91	9.34e-05			
NODAL	0.0103	0.0028	3.71	2.10e-04			
IDH1	0.0064	0.0018	3.65	2.63e-04			
KRT19	0.0086	0.0024	3.58	3.48e-04			
RORC	0.0052	0.0015	3.53	4.17e-04			
UBXN11	0.0050	0.0014	3.51	4.42e-04			
SEC22A	0.0088	0.0025	-3.51	4.43e-04			
NDC1	0.0047	0.0014	3.42	6.19e-04			
ELF3	0.0051	0.0015	3.37	7.60e-04			
GALE	0.0070	0.0021	3.36	7.77e-04			
LRP1	-0.0028	0.0008	-3.36	7.81e-04			
PAOR5	0.0041	0.0012	3.35	7.95e-04			
TRD vs. non-resi	o vs. response	0.0012	0.00				
Gene	E	SE	t	D			
ZNF418	-0.003	0.0006	-4.30	1.86e-05			
NBN	-0.001	0.001	-4.29	1.91e-05			
KRT19	-0.003	0.0006	-3.91	9.93e-05			
NODAL	-0.003	0.0008	-3.85	1.27e-04			
RORC	-0.001	0.0004	-3.49	4.99e-04			
UBXN11	-0.001	0.0004	-3.48	5.24e-04			
IDH1	-0.002	0.0005	-3.45	5.83e-04			
NDC1	-0.001	0.0004	-3.40	6.88e-04			
GLUD1	0.003	0.0007	3.40	7.01e-04			
SEC22A	0.002	0.0005	3.39	7.31e-04			
SCML4	-0.001	0.0004	-3.34	8.63e-04			
ELF3	-0.001	0.0004	-3.33	8.96e-04			
LINC01220	-0.005	0.001	-3.30	9.81e-04			
PAOR5	-0.001	0.003	-3 30	9.86e-04			
Subsample treate	ed with serotonergic a	ntidepressants, rare -	+ common variants				
TRD vs. response	e						
Gene	Ē	SE	t	n			
ZNF418	0.014	0.004	3.74	1.84e-04			
PBX3	-0.007	0.002	-3.67	2.40e-04			
PTPRU	0.007	0.002	3.55	3.85e-04			
TOMILI	0.007	0.002	3.45	5.70e-04			
HIST1H4G	-0.21	0.06	-3.44	5.75e-04			
RORC	0.008	0.002	3.42	6.24e-04			
R3HDM4	-0.012	0.004	-3.35	8.05e-04			

GZMM	-0.015	0.004	-3.35	8.07e-04
ZBTB32	0.020	0.006	3.35	8.21e-04
APBA2	0.005	0.001	3.33	8.78e-04
PAM	0.004	0.001	3.33	8.78e-04
SAMD9L	0.006	0.002	3.32	9.03e-04
TRD vs. non-res	o vs. response			
Gene	E	SE	t	р
ZNF418	-0.003	0.0007	-3.95	8.78e-05
ZBTB32	-0.004	0.001	-3.84	1.35e-04
KRT19	-0.003	0.0009	-3.60	3.49e-04
PTPRU	-0.002	0.0005	-3.59	3.52e-04
TOM1L1	-0.002	0.0005	-3.54	4.25e-04
PAPOLA	0.002	0.0006	3.54	4.25e-04
IFNA4	-0.005	0.001	-3.48	5.42e-04
UBXN11	-0.002	0.0005	-3.48	5.43e-04
GATS	-0.003	0.0008	-3.47	5.67e-04
CHRD	-0.001	0.0003	-3.43	6.39e-04
APBA2	-0.001	0.0003	-3.36	8.17e-04
ZNF680	-0.002	0.0005	-3.31	9.79e-04
Subsample treate	ed with noradrenergi	c antidepressants, rar	e + common variants	
TRD vs. response	2	-		
Gene	E	SE	t	р
DLGAP2-AS1	-0.079	0.021	-3.77	1.64e-04
EXTL1	0.013	0.0036	3.66	2.50e-04
RNF144A	-0.016	0.0049	-3.37	7.52e-04
TRD vs. non-resp	o vs. response	-		
Gene	E	SE	t	р
KCNK15	-0.005	0.001	-3.76	2.03e-04
BIN1	-0.003	0.0007	-3.70	2.55e-04
COTL1	0.003	0.0008	3.61	3.46e-04
EXTL1	-0.003	0.0008	-3.57	4.03e-04
RNF144A	0.003	0.0008	3.56	4.29e-04
ARHGEF4	0.002	0.0005	3.51	5.16e-04
PRR23A	-0.005	0.0016	-3.43	6.73e-04
CLK1	-0.002	0.0007	-3.35	8.89e-04

Supplementary Table 8: association analyses of Eigen-weighted gene set scores with the phenotypic groups. No association survived after Bonferroni correction (n of gene sets analysed: 7266). Only results with p<1e-03 are shown.

Whole sample, only rare variants					
TRD vs. response					
Gene set	Е	SE	Z	р	
GO AMINO ACID TRANSMEMBRANE TRANSPORTER	0.0006	0.0002	3.70	2.17e-04	
ACTIVITY					
GO DISULFIDE OXIDOREDUCTASE ACTIVITY	0.0009	0.0002	3.55	3.90e-04	
GO BETA AMYLOID BINDING	0.0008	0.0002	3.46	5.44e-04	
GO L AMINO ACID TRANSMEMBRANE TRANSPORTER	0.0006	0.0002	3.41	6.55e-04	
ACTIVITY					
REACTOME FGFR2C LIGAND BINDING AND	0.002	0.0005	3.39	6.92e-04	
ACTIVATION					
GO REGULATION OF THYMOCYTE AGGREGATION	0.001	0.0003	3.31	9.23e-04	
TRD vs. non-resp vs. response					
Gene set	Е	SE	t	р	
GO DISULFIDE OXIDOREDUCTASE ACTIVITY	-0.0003	6.81e-05	-3.37	7.67e-04	
GO AMINO ACID TRANSMEMBRANE TRANSPORTER	-0.0001	4.12e-05	-3.36	7.99e-04	
ACTIVITY					
GO REGULATION OF THYMOCYTE AGGREGATION	-0.0003	8.19e-05	-3.31	9.55e-04	
GO MAMMARY GLAND LOBULE DEVELOPMENT	0.0003	8.02e-05	3.31	9.77e-04	

Subsample treated with serotonergic antidepressants, only rare	e variants			
TRD vs. response				
Gene set	Е	SE	t	р
GO VASCULAR ENDOTHELIAL GROWTH FACTOR	0.0008	0.0002	3.45	5.59e-04
RECEPTOR SIGNALING PATHWAY				
TRD vs. non-resp vs. response				
Gene set	E	SE	t -	n
	0.0004	1.040.04	3.40	P 7 23a 04
	-0.0004	1.040-04	-3.40	7.230-04
DDOCESS	0.0003	1.526-04	5.59	7.490-04
CO VASCULAD ENDOTHELIAL CDOWTH FACTOD	0.0002	6 12 - 05	2.21	0.0104
GO VASCULAR ENDOTHELIAL GROWTH FACTOR	-0.0002	6.13e-05	-3.31	9.916-04
RECEPTOR SIGNALING PATHWAY	• •			
Subsample treated with noradrenergic antidepressants, only ra	re variants			
TRD vs. response	I	~~~		
Gene set	E	SE	t	р
GO REGULATION OF INSULIN SECRETION INVOLVED IN	0.0012	0.0004	3.57	3.57e-04
CELLULAR RESPONSE TO GLUCOSE STIMULUS				
GO SUMO TRANSFERASE ACTIVITY	0.0025	0.0007	3.41	5.68e-04
GO TRNA METABOLIC PROCESS	0.0008	0.0002	3.41	6.45e-04
GO RESPONSE TO COCAINE	-0.0015	0.0004	-3.39	6.92e-04
TRD vs. non-resp vs. response	•	•		
Gene set	Е	SE	t	b
GO RESPONSE TO COCAINE	0.0003	9 33e-05	3.66	2.95e-04
GO I KAPPAB KINASE NE KAPPAB SIGNALING	0.0003	9 55e-05	3 39	7.83e-04
Whole sample rare + common variants	0.0005	<i>9.33</i> 0 03	5.57	7.050 01
TDD vs. rosponso				
Cone set	Г	SE	+	n
CO AMINO ACID TRANSMEMDRANE TRANSDORTER	E	SE	1	p
GO AMINO ACID I KANSMEMBKANE I KANSPORTER	0.0006	1.52e-04	3.08	2.5/e-04
	0.0015	4 29 . 04	2.40	
GO STNAPTIC TRANSMISSION DOPAMINERGIC	-0.0015	4.286-04	-3.40	0.000-04
GO REGULATION OF CHROMOSOME ORGANIZATION	0.0003	8.30e-05	3.37	7.63e-04
GO L AMINO ACID TRANSMEMBRANE TRANSPORTER	0.0006	1.84e-04	3.35	8.02e-04
ACTIVITY				
TRD vs. non-resp vs. response	F		1	1
Gene set	E	SE	t	р
GO REGULATION OF CHROMOSOME ORGANIZATION	-7.54e-05	0.00002	-3.47	5.30e-04
GO SYNAPTIC TRANSMISSION DOPAMINERGIC	3.75e-04	0.0001	3.35	8.35e-04
Subsample treated with serotonergic antidepressants, rare + co	mmon varia	ants		
TRD vs. response				
Gene set	Е	SE	t	р
PID BCR 5PATHWAY	0.0009	0.0002	3.67	2.43e-04
PID CD40 PATHWAY	0.001	0.0004	3.63	2.84e-04
GO RESPONSE TO NICOTINE	0.001	0.0003	3 38	7 22e-04
PID TRAIL PATHWAY	0.002	0.0005	3 37	7 48e-04
GO AMINO ACID TRANSMEMBRANE TRANSPORTER	0.002	0.0003	3.37	8 93e-04
ACTIVITY	0.0007	0.0002	5.52	0.950-04
TPD vs. non-resp. vs. response				
Cone set	Г	SE	+	n
	E	SE	1 07	p 5 28- 05
	-0.0004	1.03e-04	-4.07	3.286-05
	-0.0002	0.12e-05	-3.0/	2.050-04
	-0.0003	/./6e-05	-5.50	4.92e-04
GO GLYCERALDEHYDE 3 PHOSPHATE METABOLIC	0.0005	1.51e-04	3.49	5.20e-04
PROCESS				
GO G PROTEIN COUPLED GLUTAMATE RECEPTOR	0.0004	1.13e-04	3.45	6.09e-04
SIGNALING PATHWAY				
GO AMINO ACID TRANSMEMBRANE TRANSPORTER	-0.0002	5.44e-05	-3.38	7.77e-04
ACTIVITY				
PID TRAIL PATHWAY	-0.0004	1.22e-04	-3.34	8.83e-04
Subsample treated with noradrenergic antidepressants, rare +	common va	riants		

TRD vs. response					
Gene set	E	SE	t	р	
GO RESPONSE TO COCAINE	-0.0016	0.0004	-3.73	1.92e-04	
GO REGULATION OF INSULIN SECRETION INVOLVED IN	0.0012	0.0004	3.43	6.05e-04	
CELLULAR RESPONSE TO GLUCOSE STIMULUS					
TRD vs. non-resp vs. response					
Gene set	E	SE	t	р	
GO RESPONSE TO COCAINE	0.0004	8.91e-05	4.08	5.61e-05	

Supplementary Table 9: genes (A) and gene sets (B) included in the predictive models. The order of predictors corresponds to their relative importance in the model (see also Figure 2).

Supplementary Table 9A

Whole sample	Subset treated with	Subset treated with
	serotonergic antidepressants	noradrenergic antidepressants
HAMP	LYRM1	NFKBIE
ABCD3	CACNA1I	FECH
MTFR1L	SCMH1	CPA6
HPSE	ACSM5	PLAG1
SS18L1	PTPRU	ADGRE5
NBN	REM1	HAMP
BTBD6	ZNF418	NEK8
MRGBP	MTF2	MIR3654
CPA6	RORC	STRBP
BIK	SP7	DBF4B
WWC2-AS2	PRG4	GRID1.AS1
IDH1	BIK	LZTS3
NODAL	ZNF19	NR5A2
SP/	SNRNP25	WDR97
TLCDI	CPSF6	
HSPA9	LPCAT1	
NPBWR2	CEACAM20	
	HPSE	
	LRRN4	
	PDE6G	
	CTNND1	
	HAMP	
	GATS	
	LCE1B	
	FGFBP3	
	PI15	
	RORB.AS1	
	RNASEK-C17orf49	
	ADH1A	
	HIST1H2BK	
	LOC102723824	
	NFKB1	
	AMPD2	
	IQCF5-AS1	

ARHGAP35	
MTG2	
TOM1L1	
C14orf93	
PRMT5	
RHBDF1	
PLEKHA2	
ZNF154	
PTOV1-AS2	
SIGLEC15	
FAAP20	
CCL16	
PART1	
TMEM68	
SPAM1	
CNOT8	
PMS2	
UMPS	
KIAA1024	
ZNF366	
HMGN4	
LCA5L	
KRTAP24.1	
EFCAB2	
MRPS36	
DGCR6	
DUSP23	
MBIP	
ZBTB32	
C1R	
R3HDM4	
IQCF5	
RSBN1L	
BTBD6	
GZMM	
MMP27	
GUSBP5	
VDR	
NODAL	
SLC17A4	
EMC4	
IDH1.AS1	
TCAF1	

OGFR	
ZNF599	
SMC5	
WWC2-AS2	
COL8A1	
OR5AS1	

Supplementary table 9B

Whole sample	Subset treated with	Subset treated with
	serotonergic antidepressants	noradrenergic antidepressants
GO SEGMENT SPECIFICATION	GO POSITIVE REGULATION OF	GO COP9 SIGNALOSOME
	OXIDOREDUCTASE ACTIVITY	
GO RESPONSE TO IRON ION	GO NEUROPEPTIDE RECEPTOR	GO SYNAPTIC TRANSMISSION
	BINDING	GLUTAMATERGIC
GO PROTEIN IMPORT INTO	PID CD40 PATHWAY	GO ESTROUS CYCLE
MITOCHONDRIAL MATRIX		
GO POSITIVE REGULATION OF	GO LAMIN BINDING	GO RESPIRATORY SYSTEM
AMINE TRANSPORT		PROCESS
GO BETA AMYLOID BINDING	GO SIGNAL TRANSDUCTION IN	GO RESPIRATORY CHAIN
	ABSENCE OF LIGAND	
GO INTRA S DNA DAMAGE	GO VASCULAR ENDOTHELIAL	GO TELOMERASE HOLOENZYME
CHECKPOINT	GROWTH FACTOR RECEPTOR	COMPLEX
	SIGNALING PATHWAY	
GO REGULATION OF BONE	GO ORGANIC CATION	GO AMINOACYL TRNA EDITING
DEVELOPMENT	TRANSPORT	ACTIVITY
GO NEGATIVE REGULATION OF	NABA BASEMENT MEMBRANES	GO INTRAMOLECULAR
DENDRITE DEVELOPMENT		OXIDOREDUCTASE ACTIVITY
GO FIBROBLAST GROWTH	GO UBIQUINONE METABOLIC	GO REGULATION OF HORMONE
FACTOR RECEPTOR BINDING	PROCESS	METABOLIC PROCESS
GO COP9 SIGNALOSOME	REACTOME RAF MAP KINASE	GO NEURON NEURON SYNAPTIC
	CASCADE	TRANSMISSION
GO 3 5 DNA HELICASE	GO NEGATIVE REGULATION OF	GO REGULATION OF
ACTIVITY	DEFENSE RESPONSE	TRANSLATIONAL FIDELITY
	GO REGULATION OF PEPTIDYL	GO ISOMERASE ACTIVITY
	SERINE PHOSPHORYLATION OF	
	STAT PROTEIN	
	GO SEGMENT SPECIFICATION	
	GO RESPONSE TO THYROID	
	HORMONE	
	GO NEGATIVE REGULATION OF	
	DEFENSE RESPONSE TO VIRUS	
	GO POSITIVE REGULATION OF	
	AMINE TRANSPORT	
	GO RESPONSE TO	
	TEMPERATURE STIMULUS	
	GO OUTER MITOCHONDRIAL	
	MEMBRANE PROTEIN	
	COMPLEX	
	GO BASAL LAMINA	

KEGG ONE CARBON POOL BY	
GO TAU PROTEIN BINDING	
GO RESPONSE TO ZINC ION	
GO GLYCERALDEHYDE 3 PHOSPHATE METABOLIC PROCESS	
GO NEGATIVE REGULATION OF INTRACELLULAR ESTROGEN RECEPTOR SIGNALING PATHWAY	
GO NUCLEOBASE BIOSYNTHETIC PROCESS	
REACTOME THE ACTIVATION OF ARYLSULFATASES	
NABA ECM GLYCOPROTEINS	
GO EXTRACELLULAR MATRIX	
ACTIVATION EVENTS	
 GO POSITIVE REGULATION OF FILOPODIUM ASSEMBLY	
GO RESPONSE TO IRON ION	
GO SULFURIC ESTER HYDROLASE ACTIVITY NABA CORE MATRISOME	

Supplementary Table 10: results referred to non-significant or borderline significant predictive models in the testing sample (GSRD). NA=noradrenergic. 5-HT=serotonergic. AUC=area under the curve, 95% confidence intervals are reported in parenthesis.

Predictors	Phenotype	Sample subset	Results
Pathways, rare variants only	TRD vs. response	NA antidepressants	AUC 0.50 (0.34-0.66)
	Non-response vs.	Whole testing sample	AUC 0.53 (0.45-0.61)
	response	5-HT antidepressants	AUC 0.59 (0.48-0.69)
		NA antidepressants	AUC 0.63 (0.46-0.80)
	TRD + non-response	Whole testing sample	AUC 0.56 (0.48-0.63)
	vs. response	5-HT antidepressants	AUC 0.58 (0.49-0.67)
		NA antidepressants	AUC 0.44 (0.29-0.58)
Pathways, rare and common	TRD vs. response	Whole testing sample	AUC 0.51 (0.44-0.59)
variants		5-HT antidepressants	AUC 0.53 (0.42-0.64)
		NA antidepressants	AUC 0.58 (0.42-0.74)
	Non-response vs.	Whole testing sample	AUC 0.56 (0.48-0.64)
	response	5-HT antidepressants	AUC 0.61 (0.51-0.72)
		NA antidepressants	AUC 0.60 (0.43-0.77)
	TRD + non-response	Whole testing sample	AUC 0.48 (0.41-0.55)
	vs. response	5-HT antidepressants	AUC 0.52 (0.43-0.61)
		NA antidepressants	AUC 0.61 (0.46-0.76)
Genes, rare and common	TRD vs. response	NA antidepressants	AUC 0.60 (0.45-0.76)
variants		Whole testing sample	AUC 0.59 (0.51-0.67)

No	on-response vs.	5-HT antidepressants	AUC 0.64 (0.537-0.74)
res	sponse	NA antidepressants	AUC 0.65 (0.48-0.82)
TR	RD + non-response	Whole testing sample	AUC 0.59 (0.51-0.65)
vs.	. response	5-HT antidepressants	AUC 0.52 (0.42-0.61)
		NA antidepressants	AUC 0.57 (0.42-0.72)

Supplementary Table 11: clinical-demographic characteristics of patients included from GENDEP and STAR*D studies. Only patients having both the exome and genome-wide arrays were considered. QIDS-CR=Quick Inventory of Depressive Symptomatology Clinician-Rated.

Variable	GENDEP (n=756)	STAR*D (n=959)
Age	42.18±11.52	42.79±13.58
Gender F/M	470/286	553/406
Baseline depression severity	28.85±6.75	16.28±3.17 (QIDS-CR)
Treatment	escitalopram (57%), nortriptyline (43%)	Level 1: citalopram
		Level 2: bupropion (15%), citalopram+bupropion
		(19%), citalopram + buspirone (22%), citalopram +
		cognitive therapy (5.5%), cognitive therapy (3.2%),
		sertraline (17%), venlafaxine (18.3%)
Number of previous depressive episodes	1.73±0.68	4.69±5.53
Duration of the current depressive episode	21.17± 17.29 (weeks)	1.21±1.60 (years)
Chronic depression yes/no	56/700 (>= 1 year)	184/732 (>= 2 years)
Suicidality yes/no	159/596	240/719
Phenotype distribution	TRD=103; non-responders=435; responder=218	TRD=243; non-responders=145; responders=571

Supplementary Table 12: application of the significant predictive models developed in GSRD training set in STAR*D and GENDEP. Extreme genetic percentiles were considered ≤ 20 or ≥ 80 percentiles. *Significant models.

Pathway scores as predictors – rare variants				
Whole STAR*D sample				
Genetic predictors only	Genetic predictors + clinical	Extreme genetic percentiles,	Extreme genetic percentiles, genetic	
	risk score	genetic predictors only	predictors + clinical score	
AUC 0.53 (0.49-0.58)	AUC 0.54 (0.49-0.58)	AUC 0.55 (0.48-0.62)	AUC 0.52 (0.45-0.60)	
Whole GENDEP sample				
Genetic predictors only	Genetic predictors + clinical	Extreme genetic percentiles,	Extreme genetic percentiles, genetic	
	risk score	genetic predictors only	predictors + clinical score	
AUC 0.54 (0.47-0.60)	risk score AUC 0.60 (0.54-0.65)*	genetic predictors only AUC 0.50 (0.39-0.61)	predictors + clinical score AUC 0.59 (0.47-0.70)	
AUC 0.54 (0.47-0.60)	risk score AUC 0.60 (0.54-0.65)* Sens=0.64; spec=0.52; PPV=0.39;	genetic predictors only AUC 0.50 (0.39-0.61)	predictors + clinical score AUC 0.59 (0.47-0.70)	
AUC 0.54 (0.47-0.60)	risk score AUC 0.60 (0.54-0.65)* Sens=0.64; spec=0.52; PPV=0.39; NPV=0.75	genetic predictors only AUC 0.50 (0.39-0.61)	predictors + clinical score AUC 0.59 (0.47-0.70)	

Genetic predictors only	Genetic predictors + clinical	Extreme genetic percentiles,	Extreme genetic percentiles*, genetic predictors + clinical score
AUC 0.52 (0.46-0.59)	AUC 0.54 (0.48-0.60)	AUC 0.59 (0.48-0.69)	AUC 0.61 (0.51-0.71)*
			Sens=0.35; spec=0.85; PPV=0.29;
			NPV=0.88
GENDEP sample – patients treated wit	h 5-HT antidepressants		·
Genetic predictors only	Genetic predictors + clinical	Extreme genetic percentiles,	Extreme genetic percentiles, genetic
	risk score	genetic predictors only	predictors + clinical score
AUC 0.55 (0.46-0.59)	AUC 0.50 (0.40-0.59)	AUC 0.58 (0.38-0.77)	AUC 0.52 (0.34-0.69)
Gene scores as predictors – rare a	and common variants		
Whole STAR*D sample			
Genetic predictors only	Genetic predictors + clinical	Extreme genetic percentiles,	Extreme genetic percentiles, genetic
	risk score	genetic predictors only	predictors + clinical score
AUC 0.51 (0.46-0.55)	AUC 0.55 (0.51-0.59)*	AUC 0.52 (0.45-0.59)	AUC 0.50 (0.42-0.56)
	Sens=0.38; spec=0.72; PPV=0.36;		
	NPV=0.73		
Whole GENDEP sample			1
Genetic predictors only	Genetic predictors + clinical	Extreme genetic percentiles,	Extreme genetic percentiles, genetic
	risk score	genetic predictors only	predictors + clinical score
AUC 0.50 (0.42-0.56)	AUC 0.54 (0.48-0.61)	AUC 0.53 (0.42-0.64)	AUC 0.56 (0.45-0.66)
STAR*D sample – patients treated with	n 5-HT antidepressants		1
Genetic predictors only	Genetic predictors + clinical	Extreme genetic percentiles,	Extreme genetic percentiles, genetic
	risk score	genetic predictors only	predictors + clinical score
AUC 0.55 (0.49-0.62)	AUC 0.55 (0.48-0.61)	AUC 0.55 (0.44-0.65)	AUC 0.53 (0.43-0.64)
GENDEP sample – patients treated with 5-HT antidepressants			
AUC 0.58 (0.49-0-68)	AUC 0.62 (0.53-0.72)*	AUC 0.58 (0.40-0.75)	AUC 0.57 (0.40-0.0.75)
	Sens=0.60; spec=0.67; PPV=0.36;		
	NPV=0.84		

Supplementary Figure 1: beta distributions used to estimate frequency-based weights for rare (A) and common variants (B).



Supplementary Figure 2: Flowchart of the number of patients excluded during quality control.



Supplementary Figure 3: concordance between rare variants from exome sequencing and rare variants (genotyped or imputed) from genome-wide genotyping. The total number of variants available for these comparisons was 161,130 (120,632 imputed variants and 40,497 genotyped variants).



Supplementary Figure 4: exome-wide distribution of the score (re-scaled between 20 and 100) using the described different weighting approaches. Subjects with scores outside 5 SD from the mean (red



lines) were excluded from the subsequent analyses. SO=sequence ontology project.



Supplementary Figure 5: correlation (Pearson's correlation coefficient) among gene scores obtained using different functional weighting.



Supplementary Figure 6: comparison of the distribution of rare variants between the GSRD sample (exome sequence data) and GENDEP (genome-wide and exome arrays after imputation).



References

1. Babraham Bionformatics. FastQC: A quality control tool for high throughput sequence data [Internet]. [cited 2019 Jun 18]. Available from:

http://www.bioinformatics.babraham.ac.uk/projects/fastqc/

2. FASTX-Toolkit. FASTQ/A Trimmer [Internet]. [cited 2019 Jun 18]. Available from: http://hannonlab.cshl.edu/fastx_toolkit/index.html

3. Kim D, Pertea G, Trapnell C, Pimentel H, Kelley R, Salzberg SL. TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol. 2013;14(4):R36.

4. Garrison E, Sibley T, Lee D, Marks P, Spies N, Randall J, et al. Freebayes, a haplotypebased variant detector [Internet]. [cited 2019 Jun 18]. Available from: https://github.com/ekg/freebayes

5. Zhang S, Wang B, Wan L, Li LM. Estimating Phred scores of Illumina base calls by logistic regression and sparse modeling. BMC Bioinformatics. 2017;**18**(1):335.

6. Wang Q, Shashikant CS, Jensen M, Altman NS, Girirajan S. Novel metrics to measure coverage in whole exome sequencing datasets reveal local and global non-uniformity. Sci Rep. 2017;7(1):885.

7. Fang H, Wu Y, Narzisi G, et al. Reducing INDEL calling errors in whole genome and exome sequencing data. Genome Med. 2014;**6**(10):89.

 Hutter S, Piro RM, Waszak SM, et al. No correlation between NF1 mutation position and risk of optic pathway glioma in 77 unrelated NF1 patients. Hum Genet. 2016;135(5):469–75.
 Anderson CA, Pettersson FH, Clarke GM, Cardon LR, Morris AP, Zondervan KT. Data

9. Anderson CA, Pettersson FH, Clarke GM, Cardon LR, Morris AP, Zondervan KT. Data quality control in genetic case-control association studies. Nat Protoc. 2010;**5**(9):1564–73.

10. Zhang Y, Shen X, Pan W. Adjusting for population stratification in a fine scale with principal components and sequencing data. Genet Epidemiol. 2013;**37**(8):787–801.

11. Fabbri C, Kasper S, Kautzky A, et al. Genome-wide association study of treatmentresistance in depression and meta-analysis of three independent samples. Br J Psychiatry. 2019;**214**(1):36–41.

12. McCarthy S, Das S, Kretzschmar W, et al. A reference panel of 64,976 haplotypes for genotype imputation. Nat Genet. 2016;**48**(10):1279–83.

13. Das S, Forer L, Schönherr S, et al. Next-generation genotype imputation service and methods. Nat Genet. 2016;**48**(10):1284–7.

14. Kircher M, Witten DM, Jain P, O'Roak BJ, Cooper GM, Shendure J. A general framework for estimating the relative pathogenicity of human genetic variants. Nat Genet. 2014;**46**(3):310–5.

15. Ionita-Laza I, McCallum K, Xu B, Buxbaum JD. A spectral approach integrating functional genomic annotations for coding and noncoding variants. Nat Genet. 2016;**48**(2):214–20.

16. Curtis D. Construction of an Exome-Wide Risk Score for Schizophrenia Based on a Weighted Burden Test. Ann Hum Genet. 2018;**82**(1):11–22.

17. Liberzon A, Birger C, Thorvaldsdóttir H, Ghandi M, Mesirov JP, Tamayo P. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 2015;1(6):417–25.

18. Pirooznia M, Wang T, Avramopoulos D, et al. SynaptomeDB: an ontology-based knowledgebase for synaptic genes. Bioinformatics. 2012;**28**(6):897–9.

Wray NR, Ripke S, Mattheisen M, et al. Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression. Nat Genet. 2018;50(5):668–81.
 Pardiñas AF, Holmans P, Pocklington AJ, et al. Common schizophrenia alleles are enriched

in mutation-intolerant genes and in regions under strong background selection. Nat Genet. 2018;**50**(3):381–9.

21. Purcell SM, Moran JL, Fromer M, et al. A polygenic burden of rare disruptive mutations in schizophrenia. Nature. 2014;**506**(7487):185–90.

22. Stahl EA, Breen G, Forstner AJ, et al. Genome-wide association study identifies 30 loci associated with bipolar disorder. Nat Genet. 2019;**51**(5):793–803.

23. Wang X, Zhang D, Tzeng J-Y. Pathway-guided identification of gene-gene interactions. Ann Hum Genet. 2014;**78**(6):478–91.

24. Rush AJ, Fava M, Wisniewski SR, et al. Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clin Trials. 2004;**25**(1):119–42.

25. Uher R, Perroud N, Ng MYM, et al. Genome-wide pharmacogenetics of antidepressant response in the GENDEP project. Am J Psychiatry. 2010;167(5):555–64.

26. Iniesta R, Malki K, Maier W, et al. Combining clinical variables to optimize prediction of antidepressant treatment outcomes. J Psychiatr Res. 2016;**78**:94–102.

27. Garriock HA, Kraft JB, Shyn SI, et al. A Genomewide Association Study of Citalopram Response in Major Depressive Disorder. Biological Psychiatry. 2010;**67**(2):133–8.

28. Patterson N, Price AL, Reich D. Population structure and eigenanalysis. PLoS Genet. 2006;**2**(12):e190.

29. Ionita-Laza I, Lee S, Makarov V, Buxbaum JD, Lin X. Sequence kernel association tests for the combined effect of rare and common variants. Am J Hum Genet. 2013;**92**(6):841–53.

30. Khan A, Dager SR, Cohen S, Avery DH, Scherzo B, Dunner DL. Chronicity of depressive episode in relation to antidepressant-placebo response. Neuropsychopharmacology. 1991;4(2):125–30.

31. Uher R, Perlis RH, Henigsberg N, et al. Depression symptom dimensions as predictors of antidepressant treatment outcome: replicable evidence for interest-activity symptoms. Psychol Med. 2012;**42**(5):967–80.